Learn more or see if you may qualify at https://telehealthfx.com

Educational content only — not medical advice. Talk to a licensed clinician before starting any medication. Telehealth FX is an informational and affiliate platform, not a medical provider or pharmacy, and may earn a commission. Compounded medications are not FDA-approved. Individual results vary.

Tirzepatide is the medication behind Mounjaro and Zepbound — and unlike single-receptor GLP-1s, it's a dual GIP/GLP-1 agonist. In this episode we explain what tirzepatide is, how the two-receptor mechanism works, the difference between the brands, what the research shows for weight and blood sugar, how it compares to semaglutide, and why it recently became the first medication ever approved for obstructive sleep apnea — plus the real side effects and the honest truth about stopping.

Quick clarifier: tirzepatide is the active drug. Mounjaro is approved for type 2 diabetes; Zepbound is approved for weight management and, as of December 2024, for moderate-to-severe obstructive sleep apnea in adults with obesity.

Key facts: In SURMOUNT-1, average weight loss ranged from about 16% to 22.5% over 72 weeks. In the head-to-head SURMOUNT-5 trial, tirzepatide produced about 20.2% weight loss versus 13.7% for semaglutide. In SURMOUNT-OSA, the highest tolerated doses were associated with roughly 25–29 fewer apnea/hypopnea events per hour versus placebo. Across follow-up studies, people regained roughly two-thirds of lost weight within a year of stopping.

Real risks discussed: gastrointestinal side effects; a boxed warning for thyroid C-cell tumors (not for those with a personal/family history of medullary thyroid carcinoma or MEN2); pancreatitis and gallbladder risks; a class warning for ileus (intestinal blockage). Note: a large analysis did not find a significant link between tirzepatide and the rare optic-nerve condition associated with semaglutide, though research continues.

Important: Compounded tirzepatide is not FDA-approved — the FDA does not evaluate it for safety, effectiveness, or quality — and it is not the same as branded Mounjaro or Zepbound. Prescription medications require evaluation and a prescription from a licensed clinician, and eligibility is individual. Individual results vary.

Learn more or see if you may qualify at https://telehealthfx.com

#Tirzepatide #Mounjaro #Zepbound #WeightManagement #SleepApnea #GLP1 #HealthEducation #Telehealth

Viit https://telehealthfx.com to get started.

Educational content only — not medical advice. Talk to a licensed clinician before starting any medication. Telehealth FX is an informational and affiliate platform, not a medical provider or pharmacy, and may earn a commission. Compounded medications are not FDA-approved. Individual results vary.

Semaglutide goes by a lot of names — Ozempic, Wegovy, Rybelsus, and now the new Wegovy pill — and the confusion is real. In this episode we explain what semaglutide actually is, how it works, the difference between the brands, how well it works for weight management, what the research says about heart health, how it compares to tirzepatide, the real side effects, and the honest truth about what happens when you stop.

Quick clarifier: semaglutide is the active drug. Ozempic is the injection approved for type 2 diabetes; Wegovy is the injection approved for weight management; Rybelsus is the oral tablet for type 2 diabetes. In December 2025 the FDA approved a once-daily oral semaglutide (Wegovy pill) for chronic weight management.

Key facts: In the STEP 1 trial, average weight loss with semaglutide 2.4 mg injection was about 14.9% over 68 weeks. In the OASIS 4 trial, the oral 25 mg pill produced about 13.6% average weight loss (around 16.6% with full adherence), described as similar to the injection. In the SELECT trial, semaglutide was linked to about a 20% reduction in major cardiovascular events in people with overweight/obesity and established heart disease. In the head-to-head SURMOUNT-5 trial, semaglutide produced about 13.7% weight loss versus 20.2% for tirzepatide. Across follow-up studies, people regained roughly two-thirds of lost weight within a year of stopping.

Real risks discussed: gastrointestinal side effects; a boxed warning for thyroid C-cell tumors (not for those with a personal/family history of medullary thyroid carcinoma or MEN2); pancreatitis and gallbladder risks; and an eye-condition signal still under study.

Important: Compounded semaglutide is not FDA-approved — the FDA does not evaluate it for safety, effectiveness, or quality — and it is not the same as branded Ozempic or Wegovy. Prescription medications require evaluation and a prescription from a licensed clinician, and eligibility is individual. Individual results vary.

Learn more or see if you may qualify at https://telehealthfx.com

#Semaglutide #Ozempic #Wegovy #Rybelsus #WeightManagement #GLP1 #HealthEducation #Telehealth

Visit https://losingweightrx.com to get started.

Educational content only — not medical advice. Talk to a licensed clinician before starting any medication. Telehealth FX is an informational and affiliate platform, not a medical provider or pharmacy, and may earn a commission. Compounded medications are not FDA-approved. Individual results vary.

In this episode we look at what the science actually says about how well GLP-1 medications work for weight management — and what "effective" really means once you look past the first few months. We cover how semaglutide and tirzepatide work, the headline results from the major clinical trials, the newly approved any-time-of-day GLP-1 pill, the cardiovascular findings that go beyond the scale, and the honest catch most ads skip: these medications work while you take them, and much of the lost weight tends to return after stopping.

Key facts: In the STEP 1 trial, average weight loss with semaglutide 2.4 mg was about 14.9% over 68 weeks. In SURMOUNT-1, tirzepatide produced roughly 16–22% average loss depending on dose. In the SELECT trial, semaglutide was linked to about a 20% reduction in major cardiovascular events in people with overweight/obesity and established heart disease. The newly approved oral GLP-1 showed up to about 12.4% weight loss at its highest dose over 72 weeks. Across follow-up studies, people regained roughly two-thirds of lost weight within a year of stopping.

Real risks discussed: gastrointestinal side effects; a boxed warning for thyroid C-cell tumors (not for those with a personal/family history of medullary thyroid carcinoma or MEN2); pancreatitis and gallbladder risks; and an eye-condition signal still under study.

Important: Compounded semaglutide and tirzepatide are not FDA-approved — the FDA does not evaluate them for safety, effectiveness, or quality — and they are not the same as branded Ozempic, Wegovy, Mounjaro, or Zepbound. Prescription medications require evaluation and a prescription from a licensed clinician, and eligibility is individual. Individual results vary.

Learn more or see if you may qualify at https://telehealthfx.com

#GLP1 #Semaglutide #Tirzepatide #WeightManagement #ObesityMedicine #HealthEducation #Telehealth